ArticleFrontiers in neurology2025
Hyperuricemia reduces the risk of MCI but not dementia: a cross-sectional study in Liuyang.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The study on cerebral variations and cognitive function in male patients with hyperuricemia using amide proton transfer imaging.Quantitative imaging in medicine and surgery · 2026Article
- Association of remnant cholesterol with cognitive impairment: a cross-sectional study.Frontiers in human neuroscience · 2026Article
- U-shaped association of the non-HDL/HDL ratio with cognitive impairment identified by conventional analyses and machine learning in health examination participants in Liuyang.Frontiers in human neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairments, including mild cognitive impairment (MCI) and dementia, significantly affect patients' daily functions and quality of life, contributing to a substantial societal and economic burden. The role of uric acid in cognitive function is controversial, with some studies suggesting protective effects, while others indicate increased risk of cognitive decline. Methods: A total of 1,098 participants with an average age of 69 years were included in the study. Cognitive function was assessed using the Mini-Mental State Examination. Hyperuricemia was defined as blood uric acid concentrations >420 μmol/L. Logistic regression and restricted cubic spline analysis were performed to assess the association between hyperuricemia and cognitive impairment, including MCI and dementia. Results: Hyperuricemia was associated with a lower risk of cognitive impairment (OR = 0.51, 95% CI = 0.31-0.80) and MCI (OR = 0.39, 95% CI = 0.21-0.69), particularly in individuals younger than 70 years, males, and those without hypertension or diabetes. No significant association was found between hyperuricemia and dementia (OR = 0.94, 95% CI = 0.44-1.89). There is no evidence of a non-linear relationship between hyperuricemia and cognitive impairment. Conclusion: Hyperuricemia appears to have a protective effect on cognitive function, particularly in reducing the risk of MCI, but not dementia, in specific populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.